138 related articles for article (PubMed ID: 15289103)
21. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
22. Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2.
Maskos K; Lang R; Tschesche H; Bode W
J Mol Biol; 2007 Mar; 366(4):1222-31. PubMed ID: 17196980
[TBL] [Abstract][Full Text] [Related]
23. Insight into the structural determinants for selective inhibition of matrix metalloproteinases.
Pirard B
Drug Discov Today; 2007 Aug; 12(15-16):640-6. PubMed ID: 17706545
[TBL] [Abstract][Full Text] [Related]
24. Structure of malonic acid-based inhibitors bound to human neutrophil collagenase. A new binding mode explains apparently anomalous data.
Brandstetter H; Engh RA; Von Roedern EG; Moroder L; Huber R; Bode W; Grams F
Protein Sci; 1998 Jun; 7(6):1303-9. PubMed ID: 9655333
[TBL] [Abstract][Full Text] [Related]
25. Racemic atropisomeric N,N-chelate ligands for recognizing chiral carboxylates via Zn(II) coordination: structure, fluorescence, and circular dichroism.
McCormick TM; Wang S
Inorg Chem; 2008 Nov; 47(21):10017-24. PubMed ID: 18831581
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and binding studies of bidentate Zn-chelating peptidic inhibitors of glyoxalase-I.
More SS; Vince R
Bioorg Med Chem Lett; 2007 Jul; 17(13):3793-7. PubMed ID: 17513107
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.
Nuti E; Panelli L; Casalini F; Avramova SI; Orlandini E; Santamaria S; Nencetti S; Tuccinardi T; Martinelli A; Cercignani G; D'Amelio N; Maiocchi A; Uggeri F; Rossello A
J Med Chem; 2009 Oct; 52(20):6347-61. PubMed ID: 19775099
[TBL] [Abstract][Full Text] [Related]
28. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
29. Cooperative formation of trinuclear zinc(II) complexes via complexation of a tetradentate oxime chelate ligand, salamo, and zinc(II) acetate.
Akine S; Taniguchi T; Nabeshima T
Inorg Chem; 2004 Oct; 43(20):6142-4. PubMed ID: 15446856
[TBL] [Abstract][Full Text] [Related]
30. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
[TBL] [Abstract][Full Text] [Related]
31. Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin I converting enzyme (ACE) inhibitors.
Tzakos AG; Gerothanassis IP
Chembiochem; 2005 Jun; 6(6):1089-103. PubMed ID: 15883972
[TBL] [Abstract][Full Text] [Related]
32. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups.
Puerta DT; Lewis JA; Cohen SM
J Am Chem Soc; 2004 Jul; 126(27):8388-9. PubMed ID: 15237990
[TBL] [Abstract][Full Text] [Related]
33. Quantum chemical study on the coordination environment of the catalytic zinc ion in matrix metalloproteinases.
Díaz N; Suarez D; Sordo TL
J Phys Chem B; 2006 Nov; 110(47):24222-30. PubMed ID: 17125395
[TBL] [Abstract][Full Text] [Related]
34. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G
J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231
[TBL] [Abstract][Full Text] [Related]
35. Apolactoferrin inhibits the catalytic domain of matrix metalloproteinase-2 by zinc chelation.
Newsome AL; Johnson JP; Seipelt RL; Thompson MW
Biochem Cell Biol; 2007 Oct; 85(5):563-72. PubMed ID: 17901898
[TBL] [Abstract][Full Text] [Related]
36. Identification of potent and selective MMP-13 inhibitors.
Wu J; Rush TS; Hotchandani R; Du X; Geck M; Collins E; Xu ZB; Skotnicki J; Levin JI; Lovering FE
Bioorg Med Chem Lett; 2005 Sep; 15(18):4105-9. PubMed ID: 16005220
[TBL] [Abstract][Full Text] [Related]
37. Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors.
Di Pizio A; Laghezza A; Tortorella P; Agamennone M
ChemMedChem; 2013 Sep; 8(9):1475-82, 1421. PubMed ID: 23873724
[TBL] [Abstract][Full Text] [Related]
38. Screening of matrix metalloproteinases available from the protein data bank: insights into biological functions, domain organization, and zinc binding groups.
Nicolotti O; Miscioscia TF; Leonetti F; Muncipinto G; Carotti A
J Chem Inf Model; 2007; 47(6):2439-48. PubMed ID: 17958346
[TBL] [Abstract][Full Text] [Related]
39. Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis.
Kalva S; Saranyah K; Suganya PR; Nisha M; Saleena LM
J Mol Graph Model; 2013 Jul; 44():297-310. PubMed ID: 23938376
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases.
Grolla AA; Podestà V; Chini MG; Di Micco S; Vallario A; Genazzani AA; Canonico PL; Bifulco G; Tron GC; Sorba G; Pirali T
J Med Chem; 2009 May; 52(9):2776-85. PubMed ID: 19344175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
